Novel strategies for improved cancer vaccines

References

• Srivastava PK, Old LJ. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol. Today9(3), 78–83 (1988).
   PubMedGoogle Scholar
• Melief CJ, Vasmel WL, Offringa R et al. Immunosurveillance of virus-induced tumors. Cold Spring Harb. Symp. Quant. Biol.54, 597–603 (1989).
   PubMedGoogle Scholar
• Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in human: lessons from Epstein–Barr virus. Annu. Rev. Immunol.25, 587–617 (2007).
   PubMed Web of Science ®Google Scholar
• Dalgleish A, Pandha H. Tumor antigens as surrogate markers and targets for therapy and vaccines. Adv. Cancer Res.96, 175–190 (2007).
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N. Engl. J. Med.358(25), 2704–2715 (2008).
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Harashima N, Kajigaya S et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J. Clin. Invest.118(3), 1099–1109 (2008).
   PubMed Web of Science ®Google Scholar
• Chen J, Pang XW, Liu FF et al.PLAC1/CP1 gene expression and autologous humoral immunity in gastric cancer patients. Beijing Da Xue Xue Bao38(2), 124–127 (2006).
   PubMedGoogle Scholar
• Koslowski M, Sahin U, Mitnacht-Kraus R, Seitz G, Huber C, Tureci O. A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res.67(19), 9528–9534 (2007).
   PubMed Web of Science ®Google Scholar
• Old LJ. Cancer is a somatic cell pregnancy. Cancer Immun.7, 19 (2007).
   PubMedGoogle Scholar
• Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother.58(3), 317–324 (2009).
   PubMed Web of Science ®Google Scholar
• Kruisbeek AM, Amsen D. Mechanisms underlying T-cell tolerance. Curr. Opin. Immunol.8(2), 233–244 (1996).
   PubMed Web of Science ®Google Scholar
• Stockinger B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv. Immunol.71, 229–265 (1999).
   PubMedGoogle Scholar
• Kersh GJ, Allen PM. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J. Exp. Med.184(4), 1259–1268 (1996).
   PubMed Web of Science ®Google Scholar
• Kersh GJ, Allen PM. Essential flexibility in the T-cell recognition of antigen. Nature380(6574), 495–498 (1996).
   PubMed Web of Science ®Google Scholar
• Fong L, Brockstedt D, Benike C et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol.167(12), 7150–7156 (2001).
   PubMed Web of Science ®Google Scholar
• Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood99(10), 3748–3755 (2002).
   PubMed Web of Science ®Google Scholar
• Palomba ML, Roberts WK, Dao T et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin. Cancer Res.11(1), 370–379 (2005).
   PubMed Web of Science ®Google Scholar
• Weber LW, Bowne WB, Wolchok JD et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest.102(6), 1258–1264 (1998).
   PubMed Web of Science ®Google Scholar
• Hawkins WG, Gold JS, Blachere NE et al. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J. Surg. Res.102(2), 137–143 (2002).
   PubMed Web of Science ®Google Scholar
• Lu Y, Wei YQ, Tian L et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J. Immunol.170(6), 3162–3170 (2003).
   PubMed Web of Science ®Google Scholar
• Pupa SM, Iezzi M, Di Carlo E et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res.65(3), 1071–1078 (2005).
   PubMed Web of Science ®Google Scholar
• Gallo P, Dharmapuri S, Nuzzo M et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int. J. Cancer113(1), 67–77 (2005).
   PubMed Web of Science ®Google Scholar
• Ko HJ, Kim YJ, Kim YS et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res.67(15), 7477–7486 (2007).
   PubMed Web of Science ®Google Scholar
• Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN. Vaccination with human HER-2/neu (435–443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res.66(10), 5452–5460 (2006).
   PubMed Web of Science ®Google Scholar
• Kianizad K, Marshall LA, Grinshtein N et al. Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res.67(13), 6459–6467 (2007).
   PubMed Web of Science ®Google Scholar
• Weigle WO. The induction of autoimmunity in rabbits following injection of heterologous or altered homologous thyroglobulin J. Exp. Med.121, 289–308 (1965).
   PubMed Web of Science ®Google Scholar
• Grünewald J, Tsao ML, Perera R et al. Immunochemical termination of self-tolerance. Proc. Natl Acad. Sci. USA105(32), 11276–11280 (2008).
   PubMed Web of Science ®Google Scholar
• Lazoura E, Lodding J, Farrugia W et al. Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1–8 peptide. Immunology119(3), 306–316 (2006).
   PubMed Web of Science ®Google Scholar
• Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev.222, 129–144 (2008).
   PubMed Web of Science ®Google Scholar
• Kennedy R, Celis E. T helper lymphocytes rescue CTL from activation-induced cell death. J. Immunol.177(5), 2862–2872 (2006).
   PubMed Web of Science ®Google Scholar
• Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature421(6925), 852–856 (2003).
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Shen H. Requirement for CD4 T-cell help in generating functional CD8 T-cell memory. Science300(5617), 337–339 (2003).
   PubMed Web of Science ®Google Scholar
• Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science300(5617), 339–342 (2003).
   PubMed Web of Science ®Google Scholar
• Moeller M, Haynes NM, Kershaw MH et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood106(9), 2995–3003 (2005).
   PubMed Web of Science ®Google Scholar
• Lichterfeld M, Kaufmann DE, Yu XG et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J. Exp. Med.200(6), 701–712 (2004).
   PubMed Web of Science ®Google Scholar
• Kavanagh DG, Kaufmann DE, Sunderji S et al. Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood107(5), 1963–1969 (2006).
   PubMed Web of Science ®Google Scholar
• Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-γ+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J. Immunol.169(11), 6376–6385 (2002).
   PubMed Web of Science ®Google Scholar
• Stein R, Mattes MJ, Cardillo TM et al. CD74, a new candidate target for the immunotherapy of B-cell neoplasms. Clin. Cancer Res.13(18 Pt 2), 5556s–5563s (2007).
   PubMed Web of Science ®Google Scholar
• Matza D, Kerem A, Shachar I. Invariant chain, a chain of command. Trends Immunol.24(5), 264–268 (2003).
   PubMed Web of Science ®Google Scholar
• Diebold SS, Cotten M, Koch N, Zenke M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther.8(6), 487–493 (2001).
   PubMed Web of Science ®Google Scholar
• Rowe HM, Lopes L, Ikeda Y et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol. Ther.13(2), 310–319 (2006).
   PubMed Web of Science ®Google Scholar
• Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, Christensen JP. MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J. Immunol.180(5), 3339–3346 (2008).
   PubMed Web of Science ®Google Scholar
• Grujic M, Holst PJ, Christensen JP, Thomsen AR. Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice. J. Gen. Virol.90(Pt 2), 414–422 (2009).
   PubMed Web of Science ®Google Scholar
• Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD Jr. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res.65(21), 10059–10067 (2005).
   PubMed Web of Science ®Google Scholar
• Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J. Immunother.30(1), 75–82 (2007).
   PubMed Web of Science ®Google Scholar
• Mailliard RB, Wankowicz-Kalinska A, Cai Q et al. α-type-1 polarized dendritic cells, a novel immunization tool with optimized CTL-inducing activity. Cancer Res.64(17), 5934–5937 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J. Leukoc. Biol.84(1), 319–325 (2008).
   PubMed Web of Science ®Google Scholar
• Gustafsson K, Ingelsten M, Bergqvist L, Nystrom J, Andersson B, Karlsson-Parra A. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res.68(14), 5965–5971 (2008).
   PubMed Web of Science ®Google Scholar
• Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res.68(14), 5972–5978 (2008).
   PubMed Web of Science ®Google Scholar
• Parlato S, Santini SM, Lapenta C et al. Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood98(10), 3022–3029 (2001).
   PubMed Web of Science ®Google Scholar
• Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, Olive D, Gaugler B. IFN-α skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J. Immunol.171(7), 3385–3393 (2003).
   PubMed Web of Science ®Google Scholar
• Papewalis C, Jacobs B, Wuttke M et al. IFN-α skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J. Immunol.180(3), 1462–1470 (2008).
   PubMed Web of Science ®Google Scholar
• Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM. Comparison of αtype-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine26(23), 2824–2832 (2008).
   PubMed Web of Science ®Google Scholar
• Kang SJ, Cresswell P. Calnexin, calreticulin and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain. J. Biol. Chem.277(47), 44838–44844 (2002).
   PubMed Web of Science ®Google Scholar
• Han S, Wang B, Cotter MJ et al. Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Mol. Ther.16(2), 269–279 (2008).
   PubMed Web of Science ®Google Scholar
• Chaput N, Schartz NE, Andre F et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol.172(4), 2137–2146 (2004).
   PubMed Web of Science ®Google Scholar
• Cho JA, Yeo, DJ, Son HY et al. Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int. J. Cancer114(4), 613–622 (2005).
   PubMed Web of Science ®Google Scholar
• Hao S, Bai O, Li F, Yuan J, Laferte S, Xiang J. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology120(1), 90–102 (2007).
   PubMed Web of Science ®Google Scholar
• Hao S, Liu Y, Yuan J et al. Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses. J. Immunol.179(5), 2731–2740 (2007).
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol.7(10), 790–802 (2007).
   PubMed Web of Science ®Google Scholar
• Bonifaz LC, Bonnyay DP, Charalambous A et al.In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med.199(6), 815–824 (2004).
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A, Qin F, Dakappagari N et al.In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J. Immunother.30(7), 715–726 (2007).
   PubMed Web of Science ®Google Scholar
• Yang L, Yang H, Rideout K et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol.26(3), 326–334 (2008).
   PubMed Web of Science ®Google Scholar
• Lopes L, Dewannieux M, Gileadi U et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J. Virol.82(1), 86–95 (2008).
   PubMed Web of Science ®Google Scholar
• He LZ, Crocker A, Lee J et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J. Immunol.178(10), 6259–6267 (2007).
   PubMed Web of Science ®Google Scholar
• Ramakrishna V, Treml JF, Vitale L et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol.172(5), 2845–2852 (2004).
   PubMed Web of Science ®Google Scholar
• Trumpfheller C, Finke JS, Lopez CB et al. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med.203(3), 607–617 (2006).
   PubMed Web of Science ®Google Scholar
• Gurer C, Strowig T, Brilot F et al. Targeting the nuclear antigen 1 of Epstein–Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood112(4), 1231–1239 (2008).
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Gijzen K et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood106(4), 1278–1285 (2005).
   PubMed Web of Science ®Google Scholar
• Delneste Y, Magistrelli G, Gauchat J et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity17(3), 353–362 (2002).
   PubMed Web of Science ®Google Scholar
• Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc. Natl Acad. Sci. USA87(19), 7698–7702 (1990).
   PubMed Web of Science ®Google Scholar
• Chen X, Chang CH, Goldenberg DM. Efficient binding, but moderate modulation, of human dendritic cell functions by milatuzumab, a humanized anti-CD74 monoclonal antibody. Presented at: The 50th American Society of Hematology Annual Meeting. San Francisco, CA, USA, 6–9 December 2008. Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 2649).
   Google Scholar
• Clark EA, Grabstein KH, Shu GL. Cultured human follicular dendritic cells. Growth characteristics and interactions with B lymphocytes. J. Immunol.148(11), 3327–3335 (1992).
   PubMed Web of Science ®Google Scholar
• Ding C, Wang L, Marroquin J, Yan J. Targeting of antigens to B cells augments antigen-specific T cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood112(7), 2817–2825 (2008).
   PubMed Web of Science ®Google Scholar
• Mouries J, Moron G, Schlecht G, Escriou N, Dadaglio G, Leclerc C. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood112(9), 3713–3722 (2008).
   PubMed Web of Science ®Google Scholar
• Leung SO, Goldenberg DM, Dion AS et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol. Immunol.32(17–18), 1416–1427 (1995).
   Google Scholar
• Losman MJ, Hansen HJ, Dworak H et al. Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). Cancer80(12 Suppl.), 2660–2666 (1997).
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Cardillo TM et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood104(12), 3705–3711 (2004).
   PubMed Web of Science ®Google Scholar
• Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl Acad. Sci. USA96(15), 8639–8644 (1999).
   PubMed Web of Science ®Google Scholar
• Rosinski KV, Fujii N, Mito JK et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood111(9), 4817–4826 (2008).
   PubMed Web of Science ®Google Scholar
• Kawase T, Akatsuka Y, Torikai H et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood110(3), 1055–1063 (2007).
   PubMed Web of Science ®Google Scholar
• Moreaux J, Hose D, Reme T et al. CD200 is a new prognostic factor in multiple myeloma. Blood108(13), 4194–4197 (2006).
   PubMed Web of Science ®Google Scholar
• Tonks A, Hills R, White P et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia21(3), 566–568 (2007).
   PubMed Web of Science ®Google Scholar
• Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun.364(4), 778–782 (2007).
   PubMed Web of Science ®Google Scholar
• Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol.29(10), 464–468 (2008).
   PubMed Web of Science ®Google Scholar
• Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum. Gene Ther.16(7), 799–810 (2005).
   PubMed Web of Science ®Google Scholar
• de Witte MA, Bendle GM, van den Boom MD et al. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J. Immunol.181(4), 2563–2571 (2008).
   PubMed Web of Science ®Google Scholar
• de Witte MA, Jorritsma A, Kaiser A et al. Requirements for effective antitumor responses of TCR transduced T cells. J. Immunol.181(7), 5128–5136 (2008).
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314(5796), 126–129 (2006).
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp. Biol. Med. (Maywood)232(9), 1130–1141 (2007).
   PubMed Web of Science ®Google Scholar
• North RJ. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J. Exp. Med.164(5), 1652–1666 (1986).
   PubMed Web of Science ®Google Scholar
• Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res.49(7), 1649–1654 (1989).
   PubMed Web of Science ®Google Scholar
• Ercolini AM, Ladle BH, Manning EA et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J. Exp. Med.201(10), 1591–1602 (2005).
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res.10(16), 5316–5326 (2004).
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res.12(3 Pt 1), 878–887 (2006).
   PubMed Web of Science ®Google Scholar
• Juuti A, Louhimo J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J. Clin. Pathol.59(4), 382–386 (2006).
   PubMed Web of Science ®Google Scholar
• Sharma S, Stolina M, Yang SC et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res.9(3), 961–968 (2003).
   PubMed Web of Science ®Google Scholar
• Sharma S, Yang SC, Zhu L et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res.65(12), 5211–5220 (2005).
   PubMed Web of Science ®Google Scholar
• Basu GD, Tinder TL, Bradley JM et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol.177(4), 2391–2402 (2006).
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Basu GD, Tinder TL et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol.182(1), 216–224 (2009).
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin.56(4), 226–243 (2006).
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv. Drug Deliv. Rev.60(12), 1407–1420 (2008).
   PubMed Web of Science ®Google Scholar
• Ofran Y, Ritz J. Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation. Clin. Cancer Res.14(16), 4997–4999 (2008).
   PubMed Web of Science ®Google Scholar
• Tykodi SS, Fujii N, Vigneron N et al. C19orf48 encodes a polymorphic tumor-associated antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients after allogenic hematopoietic cell transplantation. Clin. Cancer Res.14(16), 5260–5269 (2008).
   PubMed Web of Science ®Google Scholar
• Aqui NA, June CH. Post-transplant adoptive T-cell immunotherapy. Best Pract. Res. Clin. Haematol.21(3), 503–519 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson LD Jr, Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus tumor activity without exacerbating graft-versus-host disease. Blood95(7), 2426–2433 (2000).
   PubMed Web of Science ®Google Scholar
• Teshima T, Mach N, Hill GR et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res.61(1), 162–171 (2001).
   PubMed Web of Science ®Google Scholar
• Moyer JS, Maine G, Mule JJ. Early vaccination with tumor lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol. Blood Marrow Transplant.12(10), 1010–1019 (2006).
   PubMed Web of Science ®Google Scholar
• Kitawaki T, Kadowaki N, Kondo T et al. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am. J. Hematol.83(4), 315–317 (2008).
   PubMed Web of Science ®Google Scholar
• Hodge JW, Poole DJ, Aarts WM, Gomez Yafal A, Gritz L, Schlom J. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res.63(22), 7942–7949 (2003).
   PubMed Web of Science ®Google Scholar
• Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv. Drug Deliv. Rev.58(8), 931–947 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg SM, Bartido SM, Gardner JP et al. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin. Cancer Res.11(22), 8114–8121 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res.68(3), 861–869 (2008).
   PubMed Web of Science ®Google Scholar
• Barefoot B, Thornburg NJ, Barouch DH et al. Comparison of multiple vaccine vectors in a single heterologous prime–boost trial. Vaccine26(48), 6108–6118 (2008).
   PubMed Web of Science ®Google Scholar